Life Sciences

Pfizer Bextra settlement could top $2B

Pharma Compliance Alert, February 4, 2009

A $2.3 billion estimated settlement could eclipse Eli Lilly’s $1.4 billion payment to resolve allegations of off-label promotion.

Lilly’s record-setting agreement with the Department of Justice was announced on January 15. Pfizer disclosed it set aside $2.3 billion in a press release on January 26. Pfizer earmarked that money to resolve allegations regarding past off-label promotion of its non-steroidal anti-inflammatory drug Bextra, and other open investigations.

Read more about Pfizer's potentially record-settling settlement.

Comments

0 comments on “Pfizer Bextra settlement could top $2B

 

Most Popular